Alleviation of the Climacteric Symptoms with Oral Sequen tial Hormone Replacement Therapy

APICHART CHITTACHAROEN, MD*, REINER DOMHARDT, Ing**, JITTIMA MANONAI, MD*, URUSA THEPPISAI, MD*, SIEGFRIED GOLBS, DVM, PhD**

Affiliation : * Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. ** Department of Medical Affairs, Jenapharm GmbH & Co. KG, Jena, Germany.

AbstractThe efficacy of the oral hormone replacement therapy (HRT) preparation estradiol valerate/ levonorgestrel (EVILNG, Klimonorm®) in the alleviation of the menopausal complaints of peri- and postmenopausal Thai women was studied in a prospective, open, uncontrolled phase IV clinical trial. Of the 50 peri- or postmenopausal women screened, 39 completed the study. From them 31 were post menopausal and 8 peri menopausal. The participants received EV /LNG over a period of 6 cycles. The Menopause Rating Scale II (MRS II) was used to assess the effect of EV/LNG on the menopausal symptoms.
The changes in the main parameters of the MRS II during the treatment with EV !LNG showed that the general score decreased by 34.9 per cent after 3 months and was kept at the same value after 6 months of treatment. The somata-vegetative complaints decreased by 32.5 per cent after 3 months and by 35 per cent after 6 months. The pJ>ychological complaints decreased by 34.1 per cent after 3 months and by 32.9 per cent after 6 months. The urogenital complaints decreased by 29.3 per cent after 3 months, and remained at the same level after 6 months of treatment. In conclusion, the 6-months administration of the oral HRT preparation estradiol valerate/levonorgestrel caused a considerable alleviation of the climacteric symptoms in menopausal women.

Keywords : Climacteric Symptoms, Menopause, Hormone Replacement Therapy, Estradiol Valerate/ Levonorgestrel

All Articles Download

Information

Related Links